Hepatitis E
22
3
3
15
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
4.5%
1 terminated out of 22 trials
93.8%
+7.2% vs benchmark
41%
9 trials in Phase 3/4
13%
2 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 15 completed trials
Clinical Trials (22)
Seroprevalence of Hepatitis E in People With an Organ Transplant
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases
Safety and Immunogenicity Study of Thiomersal-free Hepatitis E Vaccine in People Ages 16 Years and Above
Molecular Characteristics and Prevalence of Viral Hepatitis E in Human Tissue and Cell Donors
Exposure to Hepatitis E Virus in Occitania, France
Long-term Effectiveness of a Recombinant Hepatitis E Vaccine
Safety Study of Hepatitis E Vaccine (HEV239)
Morbidity and Mortality of Hepatitis E Virus Infections in Belgium
Clinical Trial of Recombinant Hepatitis E Vaccine
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Lot Consistency Trial)
Seroprevalence Hepatitis E Infection in Healthy Blood Donors
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Chronic Hepatitis B Patients )
Ribavirin for Severe Acute and Chronic Hepatitis E Virus Infection.
HepNet Pilot Trial: Multicenter Trial for the Treatment of Chronic Hepatitis E With Sofosbuvir (SofE)
A Study on the Recombinant Hepatitis E Vaccine (Escherichia Coli) (Accelerated Vaccination Schedule)
Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine(Hecolin®)
HEV in Patients With Acute Non-A, Non-B, Non-C Hepatitis in Al-Rajhy University Hospital for Liver
Seroprevalence of Hepatitis E in HIV Positive Patients in Basque Country in 2016 (VIhVhEpb)
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(Coadministration With Recombinant Hepatitis B Vaccine)